Clinical Trial

Preventing Asthma in High Risk Kids

Study acronym: PARK
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug.
Protocol Amendment History 32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2015-10-07; most recent amendment 2025-12-02.
Status change: Recruiting → Active, Not Recruiting 2024-02-08
Status change: Not Yet Recruiting → Recruiting 2018-12-03
Trial Details
NCT Number NCT02570984
Lead Sponsor Boston Children's Hospital
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Asthma
Enrollment 200 participants
Start Date 2018-11-27
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-04